Prognostic value of serum cystatin C and its changes in patients with ST-segment elevation myocardial infarction
Frontiers in Cardiovascular Medicine · 29.07.2026 · 13
DOI: 10.3389/fcvm.2026.1816496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 29.07.2026. Verfasst von Nannan Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Serum cystatin C (Cys-C) has been established as a prognostic marker in various cardiovascular settings, but its changes and their relationship with long-term outcomes in ST-segment elevation myocardial infarction (STEMI) patients remain underexplored. Therefore, this study aims to evaluate the prognostic value of serum Cys-C concentration and its changes in predicting all-cause mortality in STEMI patients with normal or mildly impaired renal function.
Methods
This single-center, retrospective observational study enrolled 753 STEMI patients who underwent emergency percutaneous coronary intervention between February 2019 and December 2024. Serum Cys-C levels were measured at baseline and the last measurement. Patients were categorized into tertiles based on baseline Cys-C, follow-up Cys-C, and the absolute change in Cys-C. The primary endpoint was all-cause mortality.
Results
During follow-up of 627 days, 75 deaths occurred. Non-survivors had significantly higher baseline and follow-up Cys-C levels, as well as greater absolute increases in Cys-C, compared to survivors (all p < 0.001). Kaplan–Meier analysis showed significantly worse survival in the highest tertiles of baseline Cys-C (log-rank p < 0.001), follow-up Cys-C ( p < 0.0001), and Cys-C change ( p = 0.009). After multivariable adjustment, the highest tertile of baseline Cys-C was associated with a 2.20-fold increased risk of mortality (95% CI: 1.19–3.88, p = 0.012). The highest tertile of follow-up Cys-C was associated with a 3.12-fold increased risk of mortality (95% CI: 1.79–5.99, p < 0.001), while the highest tertile of Cys-C change conferred a 2.10-fold increased risk (95% CI: 1.14–3.68, p = 0.017).
Conclusion
Elevated serum Cys-C levels at baseline and the last measurement, as well as an increase in Cys-C over time, are independently associated with higher all-cause mortality in STEMI patients. Serial measurement of Cys-C may enhance risk stratification and serve as a dynamic indicator for monitoring disease progression and treatment response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency, Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Zitieren
APA
Wu, N., Li, G., Ma, W., & Zhang, M. (2026). Prognostic value of serum cystatin C and its changes in patients with ST-segment elevation myocardial infarction. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1816496
Vancouver
Wu N, Li G, Ma W, Zhang M. Prognostic value of serum cystatin C and its changes in patients with ST-segment elevation myocardial infarction. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1816496
BibTeX
@article{Wu2026,
author = {Wu, Nannan and Li, Guandong and Ma, Wenjie and Zhang, Mei},
title = {Prognostic value of serum cystatin C and its changes in patients with ST-segment elevation myocardial infarction},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1816496}
}
EUVIMED